AR072776A1 - Procesos para la produccion de 2-amino-2-[2-(4-alquil c2-20-fenil)etil]propano-1,3-dioles y a compuestos intermediarios para usar con los mismos - Google Patents

Procesos para la produccion de 2-amino-2-[2-(4-alquil c2-20-fenil)etil]propano-1,3-dioles y a compuestos intermediarios para usar con los mismos

Info

Publication number
AR072776A1
AR072776A1 ARP090100955A AR072776A1 AR 072776 A1 AR072776 A1 AR 072776A1 AR P090100955 A ARP090100955 A AR P090100955A AR 072776 A1 AR072776 A1 AR 072776A1
Authority
AR
Argentina
Prior art keywords
formula
compound
alkyl
production
salt
Prior art date
Application number
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR072776A1 publication Critical patent/AR072776A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/30—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/51—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Reivindicacion 1: Un proceso para la produccion de un compuesto de la formula (1) o una sal del mismo aceptable desde el punto de vista farmacéutico, donde R1 es hidrogeno o alquilo C1-18; que comprende: (a) reducir un compuesto de la formula (3) en donde R2 es un grupo protector; y ô- - - -ô representa un tercer enlace opcional; para formar un compuesto de la formula (2); (b) desproteger el compuesto de formula (2) para formar un compuesto de formula (1); y (c) convertir opcionalmente el compuesto de formula (1) en una sal aceptable desde el punto de vista farmacéutico. Reivindicacion 4: Un proceso para la produccion de un compuesto de la formula (2) o una sal del mismo, donde R1 es hidrogeno o alquilo C1-18; y R2 es un grupo protector; que comprende reducir un compuesto de la formula (3) o la formula (10) donde R2 es un grupo protector; cada R3 es independientemente alquilo C1-4; y ô- - - -ô representa un tercer enlace opcional. Reivindicacion 5: Un proceso para la produccion de un compuesto de la formula (3) o una sal del mismo, donde R1 es hidrogeno o alquilo C1-18; R2 es un grupo protector; y ô- - - -ô representa un tercer enlace opcional; que comprende: (a) reaccionar un compuesto de la formula (5) donde R4 es un grupo saliente; con un compuesto de la formula (6), o (b) reducir un compuesto de la formula (10), donde cada R3 es independientemente alquilo C1-4. Reivindicacion 6: Un proceso para la produccion de un compuesto de la formula (4) o una sal del mismo, donde R1 es hidrogeno o alquilo C1-18; R2 es un grupo protector; y cada R3 es independientemente alquilo C1-4; que comprende reducir un compuesto de la formula (10) donde ô- - - -ô representa un tercer enlace opcional. Reivindicacion 8: Un proceso para la produccion de un compuesto de la formula (10) o una sal del mismo, donde R1 es hidrogeno o alquilo C1-18; R2 es un grupo protector; cada R3 es independientemente alquilo C1-4; y ô- - - -ô representa un tercer enlace opcional; que comprende reaccionar un compuesto de la formula (7) con un compuesto de la formula (6). Reivindicacion 9: Un proceso para la produccion de un compuesto de la formula (7) o una sal del mismo, donde R2 es un grupo protector; cada R3 es independientemente alquilo C1-4; y R4 es un grupo saliente; que comprende reaccionar un compuesto de la formula (8) con un compuesto de la formula (9), donde R5 es un grupo saliente. Reivindicacion 10: Un proceso para la produccion de un compuesto de la formula (10) o una sal del mismo, donde R1 es hidrogeno o alquilo C1-18; R2 es un grupo protector; cada R3 es independientemente alquilo C1-4; y ô- - - -ô representa un tercer enlace opcional; que comprende los pasos de: (a) reaccionar un compuesto de la formula (8) con un compuesto de la formula (9), donde cada R4 y R5 es un grupo saliente, para obtener un compuesto de formula (7); (b) reaccionar un compuesto de la formula (6) con el compuesto que se obtuvo en el paso (a) para obtener un compuesto de formula (10).
ARP090100955 2008-03-19 2009-03-17 Procesos para la produccion de 2-amino-2-[2-(4-alquil c2-20-fenil)etil]propano-1,3-dioles y a compuestos intermediarios para usar con los mismos AR072776A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08153033 2008-03-19

Publications (1)

Publication Number Publication Date
AR072776A1 true AR072776A1 (es) 2010-09-22

Family

ID=40848446

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100955 AR072776A1 (es) 2008-03-19 2009-03-17 Procesos para la produccion de 2-amino-2-[2-(4-alquil c2-20-fenil)etil]propano-1,3-dioles y a compuestos intermediarios para usar con los mismos

Country Status (17)

Country Link
US (2) US8809571B2 (es)
EP (1) EP2268603B1 (es)
JP (2) JP5698118B2 (es)
KR (1) KR101641742B1 (es)
CN (1) CN101959845A (es)
AR (1) AR072776A1 (es)
AU (1) AU2009226975B2 (es)
BR (1) BRPI0908727A2 (es)
CA (1) CA2717934C (es)
ES (1) ES2536552T3 (es)
IL (1) IL208019A (es)
MX (1) MX2010009931A (es)
PL (1) PL2268603T3 (es)
PT (1) PT2268603E (es)
RU (1) RU2529474C2 (es)
WO (1) WO2009115534A1 (es)
ZA (1) ZA201006058B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2536552T3 (es) * 2008-03-19 2015-05-26 Novartis Ag Proceso para la preparación de 2-amino-2-[2-(4-alquil-C3-C21-fenil)etil]propano-1,3-dioles
US8766005B2 (en) 2009-07-24 2014-07-01 Ratiopharm Gmbh Process for producing fingolimod salts
WO2012071524A1 (en) 2010-11-24 2012-05-31 Ratiopharm Gmbh Arylsulfonate salts of fingolimod and processes for preparation thereof
WO2012146980A2 (en) 2011-04-29 2012-11-01 Dr. Reddy's Laboratories Ltd. Preparation of fingolimod and its salts
CZ2012406A3 (cs) 2012-06-15 2013-12-27 Zentiva, K.S. Způsob výroby fingolimodu založený na otevírání aziridinového kruhu
JP7078190B1 (ja) 2022-01-31 2022-05-31 トヨタ自動車株式会社 保持部材、射出装置、及び差し込み方向ガイド方法
JP7268779B1 (ja) 2022-01-31 2023-05-08 トヨタ自動車株式会社 保持部材

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2126658T3 (es) 1992-10-21 1999-04-01 Yoshitomi Pharmaceutical Compuesto de 2-amino-1,3-propanodiol e inmunosupresor.
IT1265101B1 (it) * 1993-07-23 1996-10-30 Erba Carlo Spa Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
DK1129066T3 (da) * 1998-11-11 2005-03-29 Novartis Ag Fremstilling af 2-amino-2-[2-(C2-20alkylphenyl)ethyl]propan-1,3-dioler
CN1144779C (zh) 1999-03-11 2004-04-07 杭州中美华东制药有限公司 制备2-[2-(4-烷基苯基)-乙基]-2-氨基-丙二醇的方法以及其中制得的中间产物
CN1169768C (zh) * 2002-04-26 2004-10-06 中国科学院上海有机化学研究所 （4－炔基）－芳香酮酸类化合物、合成方法及应用
JP3972021B2 (ja) 2003-05-28 2007-09-05 東京応化工業株式会社 プラズマディスプレイ前面板製造用未焼成積層体およびプラズマディスプレイ前面板の製造方法
JP2008530135A (ja) * 2005-02-14 2008-08-07 ユニバーシティ オブ バージニア パテント ファンデーション アミノ基およびフェニル基で置換されたシクロアルカンならびに５員の複素環を含むスフィンゴシン＝１−リン酸アゴニスト
TW200702326A (en) 2005-05-31 2007-01-16 Mitsubishi Pharma Corp 2-aminobutanol compound and its pharmaceutical use
ES2536552T3 (es) * 2008-03-19 2015-05-26 Novartis Ag Proceso para la preparación de 2-amino-2-[2-(4-alquil-C3-C21-fenil)etil]propano-1,3-dioles

Also Published As

Publication number Publication date
US20140094625A1 (en) 2014-04-03
PT2268603E (pt) 2015-06-08
WO2009115534A1 (en) 2009-09-24
CA2717934C (en) 2017-07-18
AU2009226975B2 (en) 2012-09-06
EP2268603B1 (en) 2015-04-22
US8809571B2 (en) 2014-08-19
JP5698118B2 (ja) 2015-04-08
JP2015028056A (ja) 2015-02-12
ES2536552T3 (es) 2015-05-26
CA2717934A1 (en) 2009-09-24
EP2268603A1 (en) 2011-01-05
MX2010009931A (es) 2010-09-30
IL208019A (en) 2015-10-29
KR101641742B1 (ko) 2016-07-21
CN101959845A (zh) 2011-01-26
PL2268603T3 (pl) 2015-07-31
JP5955364B2 (ja) 2016-07-20
AU2009226975A1 (en) 2009-09-24
US20110015425A1 (en) 2011-01-20
KR20100127279A (ko) 2010-12-03
US9133096B2 (en) 2015-09-15
IL208019A0 (en) 2010-12-30
RU2529474C2 (ru) 2014-09-27
JP2011515364A (ja) 2011-05-19
BRPI0908727A2 (pt) 2015-07-28
ZA201006058B (en) 2011-05-25
RU2010142397A (ru) 2012-04-27

Similar Documents

Publication Publication Date Title
AR072776A1 (es) Procesos para la produccion de 2-amino-2-[2-(4-alquil c2-20-fenil)etil]propano-1,3-dioles y a compuestos intermediarios para usar con los mismos
SV2009003157A (es) Profarmaco de compuesto de cinamida
ES2477940T3 (es) Imidazoles condensados y composiciones que los incluyen para el tratamiento de enfermedades parasitarias tales como por ejemplo malaria
PE20061450A1 (es) Proceso para la preparacion de derivados de sulfamida
AR051373A1 (es) Procedimiento para la preparacion de analogos aciclicos de nucleotidos de fosfonatos
RS53292B (en) CRYSTAL FORMS 2-THIAZOLYL-4-HINOLINYL-OXY DERIVATIVES, POWERFUL HCV INHIBITOR
AR074845A1 (es) Procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
CO6210751A2 (es) Derivados de indolinona y procedimiento para su fabricacion
UY30803A1 (es) Esteres alquilicos de amino alcoholes policiclicos n-heterociclico sustituidos, composiciones conteniéndolos, procesos de preparacion y aplicaciones
PE20140968A1 (es) Derivados de benzamida sustituida
CL2008002654A1 (es) Compuestos derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, bloqueadores de los canales hcn; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cardiopatias isquemicas, insuficiencias cardiacas tanto sistolicas como diastolicas, entre otras.
CR10206A (es) Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
CO6230986A2 (es) Compuesto de 4-piridinona y su uso para cancer
SG170794A1 (en) Process for preparation of hiv protease inhibitors
PE20142282A1 (es) Nuevos derivados de aril-quinolina
AR047523A1 (es) Procedimiento para la preparacion de 1-(2s,3s)-2-bencidril-n-(5-terc-butil-2-metoxibencil)quinuclidin-3-amina
EA201000257A1 (ru) Новый способ синтеза (7-метокси-l-нафтил) ацетонитрила и применение в синтезе агомелатина
UA113615C2 (xx) Спосіб отримання 2-аміно-n-(2,2,2-трифторетил)ацетаміду
CO6231027A2 (es) Metodos e intermediarios para preparar compuestos de lactama lactoma de 8 atomos de carbono activos como inhibidores de renina
EA200870038A1 (ru) Способ получения аминов
AR074593A1 (es) Benzotiazol amidas para la deteccion del peptido beta amiloide
AR081893A1 (es) Derivados de acido 1-(2-fluorobifenil-4-il)-alquil carboxilico para la terapia de la amiloidosis transtiretina
IN2015DN02424A (es)
AR082881A1 (es) Proceso para preparar un derivado de piperidina, intermediario para sintetizar un medicamento
UY29485A1 (es) Esteres alquílicos de aminoalcoholes cíclicos, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones

Legal Events

Date Code Title Description
FB Suspension of granting procedure